Dipeptidyl peptidase‐IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. (June 2016)

• Record Type: Journal Article
• Authors: García, M.; Aranburu, M. A.; Palacios‐Zabalza, I.; Lertxundi, U.; Aguirre, C.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 41:Number 3(2016:Jun.)
• Page Start: 368
• Page End: 370
• Publication Date: 2016-06
• Subjects: adverse drug reactions -- bullous pemphigoid -- gliptins; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12397
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance. Case summary: A 74‐year‐old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal. What is new and conclusion: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease. Abstract : Bullous pemphigoid has been associated with gliptins. We describe a case and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance (table1 ). The findings show a disproportionality for bullous pemphigoid and gliptins, except alogliptin (table3 ) and extend the evidence associating gliptins with this condition.